Novel Cancer Therapeutics
Semorex has discovered a novel, broad class of small molecule compounds that exhibit potent and selective anti-cancer activity against both solid tumors and hematological malignancies. The most striking attribute of our compounds is their lack of toxicity in mice models; all current anti-cancer therapies exhibit significant toxic profiles. This renders our discovery a potential breakthrough in oncology.
Below is a representative result of an experiment with one of the compounds (SEM007), comparing placebo-treated (lower) and SEM007-treated (upper) mice, injected with PC3 human prostate cancer cells, after 80 days. The work was done in collaboration with Prof. Michael Firer and his group in Ariel University.
Novel Proprietary Diagnostic for Systemic Fungal Infection (SFI)
Systemic fungal infection (SFI) is a life-threatening disease affecting a growing number of immunocompromised patients. Mortality rates are high and effective treatment is hampered by the lack of rapid and reliable diagnosis. Fungal culturing, the current “gold standard”, takes days. A diagnostic is urgently needed in order to provide appropriate and timely treatment for infected patients or to rule out SFI and pursue alternative disease states responsible for patient symptoms. Semorex has developed a novel diagnostic approach for rapid and reliable SFI diagnosis which answers this need.
Protein Imprinted Polymers (PIP)
Semorex has developed a novel proprietary platform technology for the selective recognition and binding of proteins. Our technology, based upon the molecularly imprinted polymer (MIP) approach, has potential wide-ranging applications in pharmaceuticals and diagnostics. As a therapeutic agent, PIPs can bind and neutralize the biological activity of selected proteins, similar to antibodies. In the diagnostic arena, PIPs can be used to develop point-of-care devices for diagnosing diseases and for detection of toxic proteins in defense and homeland security applications